The South Korean health authority is to authorize 30-percent reimbursed pricing reduction in every dose of Eisai Korea’s Symbenda injection (bendamustine hydrochloride). After a year, the injection’s pricing would be brought down again by 23.5 percent due to the expired weighted pricing benefit. Novartis Korea’s Afinitor (everolimus) is to maintain the weighted pricing benefit on each dose for two years, and they would be also reduced by 23.5 percent after the benefit expiration.

South Korea’s Ministry of Health and Welfare (MOHW) is to revise and enforce the List of Reimbursed Drugs and Upper Limit Pricing with the said details as of Apr. 1.

◆Weighted pricing benefit expires: